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Abstract 
Genetic studies have provided increasing evidence that ceramide homeostasis plays a role in 
neurodegenerative diseases including Parkinson's disease (PD). It is known that the relative amounts of 
different ceramide molecular species, as defined by their fatty acyl chain length, regulate ceramide 
function in lipid membranes and in signaling pathways. In the present study we used a comprehensive 
sphingolipidomic case-control approach to determine the effects of PD on ceramide composition in 
postmortem brain tissue from the anterior cingulate cortex (a region with significant PD pathology) and 
the occipital cortex (spared in PD), also assessing mRNA expression of the major ceramide synthase 
genes that regulate ceramide acyl chain composition in the same tissue using quantitative PCR. In PD 
anterior cingulate cortex but not occipital cortex, total ceramide and sphingomyelin levels were reduced 
from control levels by 53% (P < 0.001) and 42% (P < 0.001), respectively. Of the 13 ceramide and 15 
sphingomyelin molecular lipid species identified and quantified, there was a significant shift in the 
ceramide acyl chain composition toward shorter acyl chain length in the PD anterior cingulate cortex. This 
PD-associated change in ceramide acyl chain composition was accompanied by an upregulation of 
ceramide synthase-1 gene expression, which we consider may represent a response to reduced ceramide 
levels. These data suggest a significant shift in ceramide function in lipid membranes and signaling 
pathways occurs in regions with PD pathology. Identifying the regulatory mechanisms precipitating this 
change may provide novel targets for future therapeutics. 
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ABSTRACT (237/250 words) 
Genetic studies have provided increasing evidence that ceramide homeostasis plays a role in 
neurodegenerative diseases including Parkinson’s disease (PD). It is known that the relative 
amounts of different ceramide molecular species, as defined by their fatty acyl chain length, 
regulate ceramide function in lipid membranes and in signaling pathways. For this reason we 
used a comprehensive sphingolipidomic case-control approach to determine the effects of PD 
on ceramide composition in postmortem brain tissue from the anterior cingulate cortex (ACC, 
a region with significant PD pathology) and the occipital cortex (OCC, spared in PD), also 
assessing mRNA expression of the major CerS genes that regulate ceramide acyl chain 
composition in the same tissue using quantitative PCR. In PD ACC but not OCC, total 
ceramide and sphingomyelin levels were reduced from control levels by 53% (p < 0.001) and 
42% (p < 0.001) respectively. Of the 13 ceramide (d18:1) and 15 sphingomyelin (d18:1) 
molecular lipid species identified and quantified, there was a significant shift in the ceramide 
acyl chain composition towards shorter acyl chain length in the PD ACC. This PD-associated 
change in ceramide acyl chain composition was accompanied by an upregulation of CerS1 
gene expression, which we consider may represent a response to reduced ceramide levels. 
These data suggest a significant shift in ceramide function in lipid membranes and signalling 
pathways occurs in regions with PD pathology. Identifying the regulatory mechanisms 
precipitating this change may provide novel targets for future therapeutics. 
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INTRODUCTION 
Parkinson’s disease (PD) is a neurodegenerative movement disorder with a prevalence of 
approximately 1-2% of the population over 65 years increasing to 3-5% in people over 85 
years old 1, 2. The pathological hallmarks of PD include the specific loss of dopaminergic 
neurons in the substantia nigra pars compacta (SN) and the formation of Lewy bodies and 
Lewy neurites that are composed of aggregated alpha-synuclein (α-syn) protein and other 
components including lipids 3-5. Lewy pathologies occur progressively in a proportion of 
selective neurons located in the brainstem, temporal mesocortex and neocortex 3, 6-8. Severe 
destruction of the SN and involvement of the amygdala and the anterior cingulate cortex 
(ACC) occur relatively early after the onset of clinical symptoms, whereas the occipital 
cortex is pathologically spared 3, 6-8. 
 
There has been a recent surge of interest in the role that altered sphingolipid homeostasis may 
play in neurodegenerative diseases including PD 9-14. Ceramide is a component of all major 
sphingolipid species in the brain including sphingomyelins (SMs) and glycosphingolipids 
(GSLs) and also plays a crucial role in regulating cellular membrane structure, in apoptosis 
and as a signaling molecule after its phosphorylation by ceramide kinase 15-20. The ceramide 
molecule comprises a sphingoid base to which one of several distinct fatty acid species is 
attached through an N-acyl linkage. The N-acylation reaction is mediated by a family of 
ceramide synthase (CerS) enzymes (CerS1-6) that each utilize a different restricted subset of 
fatty acyl CoA species 20. 
 
Ceramide may be generated through three main pathways (Fig 1): (i) de novo synthesis 
beginning with serine and palmitoyl-CoA, (ii) via the breakdown of sphingomyelin by 
sphingomyelinase, and (iii) by the breakdown of glucosylceramide by glucosylceramidase 
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(GCase) 21. The latter route for ceramide production, also known as the salvage pathway, is 
the most energy efficient mechanism for ceramide generation in post-mitotic cells and is 
thought to account for 50% to 90% of sphingolipid production depending on the lipid 
molecular species and the cell type 22, 23. Any pathological changes that impair the salvage 
pathway could therefore eventually have an impact on cellular membrane structure and 
signalling pathways 22-24. It is highly relevant that mutations in the GBA gene (that encodes 
GCase) confer increased risk for PD 25-27. Intriguingly, GCase levels and activity are reduced 
in several brain regions in both sporadic PD and PD cases carrying GBA mutations as 
compared to healthy controls 28. In vitro studies suggest that increased α-syn levels may 
impair GCase trafficking and also decrease its enzyme activity 28, 29. Overall, the prediction 
would be that these changes in GCase levels and/or activity would reduce cerebral ceramide 
levels in PD. 
 
In the context of the function of ceramide in the brain and in neurodegenerative diseases, it is 
clear that it is not only the overall amount of ceramide that is important, but the relative 
amounts of the different ceramide molecular species as defined by their fatty acyl chain 
length. For example, changes in ceramide fatty acyl chain length can affect membrane order, 
membrane lipid peroxidation, mitochondrial function and apoptotic pathways in a distinct 
manner 14, 30-33. There are currently only limited data available regarding how cerebral 
ceramide acyl chain composition may change in PD and no data on how this may correlate 
with the expression of the CerS genes that control this diversity of ceramide molecular 
species.  
 
In the current study we have used a sphingolipidomics case-control approach to determine the 
effects of PD on ceramide composition in postmortem brain tissue from the anterior cingulate 
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cortex (ACC) and the occipital cortex (OCC). None of the cases or controls analysed in this 
study had known GBA mutations. The expression of the major CerS genes in the brain was 
also assessed at the mRNA level using quantitative PCR (qPCR). 
 
MATERIALS AND METHODS 
Materials  
Methyl-tert-butyl ether (MTBE), chloroform and methanol were HPLC grade and purchased 
from Thermo Scientific, Scoresby, VIC, Australia. Analytical grade butylated 
hydroxytoluene (BHT) and sodium hydroxide (98% minimum) were from Sigma Aldrich, 
Sydney, NSW, Australia and analytical grade ammonium acetate was from Crown Scientific, 
Moorebank, NSW, Australia. Screw thread vials (4 mL) and wide mouth vials (1.8 mL) with 
PTFE/silicone septa caps were from Grace Davison, Rowville, VIC, Australia. The internal 
standard mixture contained 75 µM CerPCho(d18:0/12:0) and 75 µM Cer(d18:1/10:0) in 
chloroform/methanol (2:1, vol:vol); Avanti Polar Lipids purchased from Auspep, 
Tullamarine, VIC, Australia. 
 
Human Brain Tissue 
Frozen brain grey matter and white matter samples from 10 control cases and 9 sporadic PD 
cases were received from the Sydney Brain Bank and the NSW Tissue Resource Centre. 
Standardized clinicopathological criteria were used for diagnosis with no case or control 
having any evidence of significant neuropathology other than PD 34. The cohorts were 
matched for both age (PD 77.8 + 1.9 y, controls 74.7 + 2.9 y, mean + SE) and postmortem 
interval (Con 22.0 + 4.8 h, PD 18.4 + 2.9 h, mean + SE) and an absence of common GBA 
mutations that account for 70% of causative GD alleles in non-Jewish populations (GM 
Halliday and E Sidransky, unpublished data). These variables will not be evaluated further. 
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Full demographic details are provided in Table 1. Ethics approval was from the University of 
New South Wales Human Research Ethics Committee and the University of Wollongong 
Human Research Ethics Committee. Approximately 100 mg of frozen brain tissue from the 
ACC and OCC was pulverized over dry ice and two aliquots of approximately 50 mg were 
accurately weighed stored at -80°C until required for lipid or qPCR analysis. 
 
Sphingolipid extraction and analysis by mass spectrometry 
The lipid extraction and mass spectrometry analysis was performed as previously described 
in detail 35. In brief, approximately 15 mg of pulverised human brain tissue was accurately 
weighed directly into each 0.5 mL Precellys® tube (Sapphire Bioscience, Waterloo, NSW, 
Australia) and homogenised in 300 µL ice-cold methanol containing internal standards (4 µL 
/mg tissue) and BHT (0.01% w/v), using a Precellys®24 bead homogeniser (Bertin 
Technologies; 2 x 30 sec at 6000 rpm). After transferring the homogenate to a 4 mL glass 
vial, the Precellys tube was rinsed with 162 µL methanol and 1540 µL MTBE was added to 
the glass vial (final MTBE/methanol ratio 10:3, vol:vol). Following overnight 
extraction/hydrolysis (with 0.7M sodium hydroxide), 253 µL of 0.15M ammonium acetate 
was added and the organic (upper) phase was collected in a 4 mL vial. The original 
homogenate was re-extracted by addition of 205 µL of the upper phase 
MTBE/methanol/0.15M ammonium acetate and combining the upper phase with the first 
extract. This lipid extract was then dried under nitrogen at 37°C and resuspended in 
chloroform/methanol (1:2, vol:vol). 
 
The lipid extracts were analysed via ESI-MS using a hybrid triple quadrupole ion trap mass 
spectrometer (QTRAP® 5500, AB SCIEX, Framingham, Massachusetts, USA) and an 
attached chip-based, automated nanospray source (Triversa Nanomate®, Advion, Ithaca, NY, 
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USA). Sphingolipid species were quantified using AB SCIEX Lipidview™ Software 
(Framingham, Massachusetts, USA; see 36) as described previously 35. The processing 
settings for Lipidview™ were: mass tolerance 0.5, minimum % intensity 0 and minimum S/N 
50.  
 
RNA extraction and ceramide synthase analysis by qPCR 
The qPCR analysis of human brain samples was performed as described previously 37 with 
minor modifications. In brief, approximately 30 mg of pulverised human brain tissue was 
accurately weighed directly into each 0.5 mL Precellys® tube (Sapphire Bioscience, 
Waterloo, NSW, Australia) and homogenised in 300 µL TRI reagent using a Precellys®24 
bead homogeniser (Bertin Technologies) with the following settings: 2 x 10 sec at 5500 rpm 
with 10 sec break (based on recommendations from Bertin Technologies). The RNA 
concentration was determined spectrophometrically with a Nanodrop 1000 (Thermo 
scientific, Wilmington, DE). Two µg of total RNA was used for reverse transcription with 
oligo dT(18) primer according to the instructions provided with the Tetro cDNA Synthesis kit 
(Bioline, Sydney, Australia). Quantitative real-time PCR was carried out in a Roche 
Lightcycler® 480 real-time PCR system using SensiFAST SYBR No-ROX kit (Bioline, 
Sydney, Australia), following the manufacturer’s protocol. Analyses were performed in 
duplicate, and CerS gene expression was normalised to cyclophilin A mRNA levels. The 
level of expression for each gene was calculated using the comparative threshold cycle (Ct) 
value method using the formula 2-ΔΔCt (where ΔΔCt = ΔCt sample – ΔCt reference) as 
described previously 38. 
 
All primers were purchased from Sigma (Castle Hill, Australia) and details of the sequences 
are as follows: Cyclophilin A (F: AGGGTTCCTGCTTTCACAGA and R: 
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GTCTTGGCAGTGCAGATGAA), CerS1 (F: ACGCTACGCTATACATGGACAC and R: 
AGGAGGAGACGATGAGGATGAG), CerS2 (F: CCGATTACCTGCTGGAGTCAG and 
R: GGCGAAGACGATGAAGATGTTG), CerS4 (F: CTTCGTGGCGGTCATCCTG and R: 
TGTAACAGCAGCACCAGAGAG), CerS5 (F: GCCATCGGAGGAATCAGGAC and R: 
GCCAGCACTGTCGGATGTC) and CerS6 (F: GGGATCTTAGCCTGGTTCTGG and R: 
GCCTCCTCCGTGTTCTTCAG). 
 
Statistical analyses 
Statistical analyses were performed using SPSS Statistics v19.0.0 (IBM, NY, USA). All 
results are expressed as mean ± standard error with p < 0.05 set as the level of significance. 
Group data were tested for normality using Shapiro-Wilk W test and homogeneity of 
variance using a 2-sided F Test. Multivariate analysis of covariance was used to assess the 
significance of the difference between PD and control with acyl chain structure by region as 
the dependent variable, case as the group variable and age and post mortem interval as 
covariates. The analysis of the mRNA data was conducted using a linear mixed model. To 
control for multiple comparisons additional post hoc comparisons were conducted using the 
method of Benjamini and Hochberg 39, these analyses were conducted using the p.adjust 
command in the package “stats” in R version 2.15.2 (R Core Development Team)40. 
 
 
RESULTS 
Ceramide analysis 
As ceramide concentration and acyl chain composition are postulated to be important in 
neurodegenerative diseases 9, 30, we conducted a detailed analysis of the major ceramide 
molecular species in human control and PD brain samples. A quantitative (nmol/g tissue wet 
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weight) comparison between control and PD ceramide species for grey matter samples 
obtained from the ACC and OCC is shown in Table 2. A total of 13 ceramide species were 
detected in both regions, with fatty acyl chain lengths ranging from C16 – C26. The total 
ceramide concentration in the PD ACC was significantly lower (53%) than in the control 
ACC. Significant reductions in most individual ceramide species were observed in the PD 
ACC samples. The greatest reductions were detected in Cer(d18:1/22:0), Cer(d18:1/23:0) and 
Cer(d18:1/24:1) with approximately 60% lower levels in PD relative to control. In contrast, 
no significant changes in the concentration of any ceramide species were detected when the 
OCC samples were compared. While there were more males in the PD cohort (n = 7) 
compared to the control cohort (n = 5), analysis of the sphingolipidomic mass spectrometry 
data for an influence of gender revealed there were no significant differences (SK Abbott and 
B Garner, unpublished data). The gender of the cohorts is therefore unlikely to confound the 
disease-status comparisons.  
 
In order to directly compare the distribution of ceramide fatty acyl chains in the control and 
PD samples, the data were also expressed in units of mol % (Fig 2). As expected 41, by far the 
two most abundant ceramide species detected in both the ACC and OCC were 
Cer(d18:1/18:0) and Cer(d18:1/24:1). Importantly, this analysis revealed a significant 
increase in C18:0 acyl chain content accompanied by a significant decrease in C24:1 acyl 
chain content in the PD ACC compared to control ACC (Fig 2). These changes remained 
significant when adjustment was made for multiple comparisons (P = 0.026 for both 
comparisons). This change in ceramide acyl composition was not present in the OCC sample 
comparison. There were additional quantitatively minor changes in acyl chain composition in 
the PD ACC compared to control ACC, overall indicating a shift from longer to shorter 
ceramide acyl chain composition in the PD cohort (Fig 2). 
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Sphingomyelin analysis 
We also analysed SM concentration and acyl chain composition in the same grey matter 
samples used for the ceramide analysis described above. Similar to the ceramide results, total 
SM levels were significantly decreased (42%) in the PD ACC compared to the control ACC, 
whereas there were no significant differences observed when the SM content of the control 
OCC and PD OCC were compared (Supplementary Table 1). When assessing SM acyl 
chain composition using a mol % analysis, several significant differences were revealed. 
Notably, in the PD ACC significant decreases in C23:0, C24:1 and C26:1 were observed and 
these were accompanied by significantly increased C18:1 and C20:0 levels (and a non-
significant trend for a 15% increase in C18:0) as compared to the control ACC. Similar to the 
changes in ceramide acyl chain composition, the SM data in general also suggest a shift from 
longer to shorter acyl chain composition in the PD cohort. 
 
SM is present in the cellular membranes of all brain cell types, however, the vast majority of 
SM in the brain is within myelin. Since white matter is highly enriched in myelin, and thus 
myelin lipids, we conducted an additional assessment of white matter samples derived from 
both the ACC and OCC of control samples and PD cases. The PD-associated changes in 
ceramide and SM absolute amounts and acyl chain length we detected in the grey matter 
ACC samples were not replicated in the white matter ACC (Supplementary Table 2 and 3). 
This suggests that the grey matter ACC changes are unlikely to be due to myelin lipid 
changes. Interestingly, we detected a significant decrease in several white matter ceramide 
and SM species in the PD OCC compared to the control OCC (Supplementary Table 2 and 
3). 
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Ceramide synthase gene expression 
In order to examine a possible underlying cause of the shift from longer to shorter ceramide 
acyl chain composition in grey matter samples from the PD ACC cohort, we next examined 
grey matter samples for the expression of the 5 CerS (LASS) genes that are expressed in the 
human brain (CerS1, CerS2, CerS4, CerS5 and CerS6). CerS1 and CerS4 preferentially attach 
C18 and C20 fatty acyl chains to dihydrosphinganine to form C18 and C20 
dihydroceramides. These dihydroceramides are then converted to C18 and C20 ceramides via 
dihydroceramide desaturase 14. The expression of CerS1 and CerS4 mRNA was significantly 
increased by approximately 2-fold and 3-fold, respectively, in the PD ACC compared to the 
control ACC (Fig 3). After correction for multiple comparisons the differences in CerS1 
remained significant whereas the differences in CerS4 were no longer signficiant (Fig 3). The 
change in ACC CerS gene expression is consistent with the PD-associated increases in C18, 
C20 and C16 ceramide species we detected using the sphingolipidomics analysis described 
above. There was no significant change in CerS2 mRNA levels in the PD ACC compared to 
the control ACC (Fig 3). CerS2 is predicted to control the synthesis of C24 ceramides in the 
brain. It is therefore plausible that the lack of change in CerS2 accompanied by increases in 
CerS1 contributes to the changes in ceramide (and SM) acyl chain composition we detected 
in the PD ACC (Fig 2). 
 
In contrast to the PD-associated changes in CerS gene expression in the ACC, we did not 
detect an increase in CerS mRNA in the PD OCC (Fig 3). This is again consistent with the 
lack of significant changes in ceramide acyl chain length in the PD OCC compared to the 
control OCC (Fig 2). For reasons that remain unclear, in the PD OCC CerS5 expression was 
reduced. A non-significant trend for increased Cer6 expression might be predicted to result in 
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no net change in ceramide acyl chain composition as CerS5 and CerS6 have overlapping 
substrate specificity (e.g. for C16 fatty acyl CoA). 
 
 
 
Discussion 
Although a strong rationale has been provided suggesting that altered ceramide metabolism 
may contribute to PD 9-14, there is very little data available regarding the molecular structure 
and levels of post-mortem brain ceramides in PD patients. In the present study we show that 
overall grey matter ceramide and SM levels are reduced in PD ACC, a brain region that 
contains Lewy body pathology from around Braak Stage IV onwards 3, 6-8. In contrast, such 
reductions in ceramide and SM were not observed in the PD OCC, a brain region that is 
spared PD pathology; although in the latter case, changes in white matter sphingolipids were 
observed. As ceramide acyl chain structure has a major influence on the biological function 
of this class of lipids 14, 30-33, it is also highly significant that our data revealed for the first 
time a shift in ceramide acyl chain composition, with PD ACC ceramide species containing 
more short chain ceramides (e.g. C16:0, C18:0 and C18:1) at the expense of long chain 
ceramides (e.g. C23:0 and C24:1). What drives these changes cannot be determined from this 
(or any) post-mortem study; however, based on previous work and our current analysis of 
CerS mRNA expression, we provide one plausible mechanistic explanation. 
 
As noted above, a major source of ceramide generation in the brain is thought to be via the 
salvage pathway. There is strong evidence that reduced GCase levels and activity are 
associated with PD 25-29 and, consistent with the data presented herein, this would be 
predicted to lead to a reduction in total ceramide levels in affected PD brain tissue. This loss 
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of GCase activity may indeed underlie the association of GBA mutations with increased PD 
risk. Interactions between GCase activity, α-synuclein and PINK1 have also been proposed 
to modulate ceramide metabolism in PD 29, 42. Intriguingly, recent data suggests that a number 
of additional genes associated with Lewy body pathology may also play a role in ceramide 
metabolism 9. For example, PANK2 and PLA2G6, which encode pantothenate kinase and 
phospholipase A2, respectively, are associated with two neurodegenerative disorders 
(Neurodegeneration with brain iron accumulation 1 and 2) that have Lewy body inclusions 9. 
Pantothenate kinase regulates CoA biosynthesis and phospholipase A2 activation promotes 
SMase-mediated generation of ceramide from SM 43. It is also possible to link LRRK2 
mutations with ceramide metabolism in PD as mutant LRRK2 interaction with parkin induces 
neuron death 44, most likely by inhibiting the normal function of parkin in preventing 
ceramide-induced cell death 45. Overall, these studies highlight that there are a number of 
pathways associated with PD that are predicted to result in altered ceramide metabolism and 
potentially reduced ceramide levels in affected PD brain tissue. 
 
The abovementioned examples do not, however, provide a mechanistic explanation for the 
alterations in ceramide acyl chain composition that we have detected. The simplest 
explanation for the shift in ceramide acyl chain composition, with increased short-chain 
ceramides and decreased long-chain ceramides in PD, is that a homeostatic response to 
reductions in ceramide generated through the salvage pathway is evoked in PD. This 
postulated activation of de novo synthesis is supported by the selective increases in specific 
CerS genes in the PD tissues that match the observed changes in ceramide acyl chain 
compositions. For reasons that remain to be defined, the induction of CerS gene expression in 
the PD ACC did not match the expression of these genes in the control brain tissues (e.g. in 
the PD ACC we observed a 2-fold upregulation CerS1 with no significant change in CerS2). 
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Regardless of the reason for the preferential induction of specific CerS genes in the PD brain, 
the consequent shift in ceramide acyl chain content may have physiological consequences. 
Although it is tempting to speculate that the PD-associated increase in short acyl chain 
ceramides may promote cellular apoptosis 32, the fact that the overall ceramide concentrations 
are reduced may to a degree circumvent this. A decrease in ceramide acyl chain length could 
also have an impact on membrane lipid order, lipid-lipid and lipid-protein interactions, 
signalling pathways and potentially on membrane lipid peroxidation reactions 12, 24, 46-48. In a 
previous study using an independent cohort of control and PD samples we conducted a broad 
liquid chromatography – mass spectrometry (LC-MS) lipidomics analysis of late stage (7/10 
PD cases were Braak stage V) PD ACC samples 37. In this earlier analysis we were able to 
accurately quantify 6 Cer(d18:1) molecular species. Interestingly, this earlier study also 
indicted an increase in the relative distribution of Cer(d18:1/18:0) and Cer(d18:1/20:0) in the 
ACC but not in OCC 37. The functional implications that altered ceramide acyl chain 
composition may have in PD neurodegeneration therefore appear to be worth exploring in 
future studies. 
 
In summary, we have shown that decreased levels of ceramide occur selectively in a brain 
region with PD pathology. This may be due to an impairment of the salvage pathway for 
ceramide generation that is not adequately compensated for by upregulated de novo synthesis. 
Induction of CerS1 gene expression in the same affected region with PD may represent a 
response to the reduced ceramide levels. The specific pattern of CerS gene induction detected 
matches the alterations in ceramide acyl chain structures we detected in the PD tissues. 
Altered ceramide metabolism occurs in PD and may play an important but as yet undefined 
functional role in the ongoing neurodegeneration observed. 
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FIGURE LEGENDS 
 
 
Figure 1. Ceramide homeostasis overview. Ceramide may be generated through de novo 
synthesis, beginning with serine and palmitoyl-CoA, or via the salvage pathway that involves 
the breakdown of sphingomyelin by sphingomyelinase, and the breakdown of 
glucosylceramide and galactosylceramide by specific glycosylceramidases. Ceramide 
synthases play a major role in the de novo synthesis pathway and also are involved in 
sphingosine recycling. Reactions contributing to the salvage pathway are indicated by the 
broken arrows. SPT, serine palmitoyl transferase; 3KR, 3-ketosphinganine reductase; CerS1-
6, ceramide synthases 1-6; DES, dihydroceramide desaturase; GCS, glucosylceramide 
synthase; GCase, glucosyl ceramidase; CGT, ceramide glactosyl transferase; GalC, galactosyl 
ceramidase; SMase, sphingomyelinase; SMS, sphingomyelin synthase; FA-CoA, fatty acyl 
CoA; GSL, glycosphingolipid; Glc-ceramide, glucosylceramide; Gal-ceramide, 
galactosylceramide; S1P, sphingosine-1-phosphate. 
 
 
Figure 2. Comparison of ceramide acyl chain structure in control and PD brain samples. 
Control (n = 10) and PD (n = 9) tissues were collected from (A) the anterior cingulate cortex 
(“ACC”) and (B) the occipital cortex (“OCC”). Lipids were extracted and analysed using a 
sphingolipidomics mass spectrometry approach. The data indicates the relative percentage 
(mol%) composition that each of the indicated fatty acyl chain structures contributes to the 
ceramide (d18:1) lipid molecular species. Control samples are indicated by the grey bars and 
PD samples are indicated by the black bars. Values are mean ± SE. * P < 0.05 using a 
multivariate analysis of covariance with ACC and OCC values as the dependent variable, 
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case as the grouping variable, and age and post-mortem interval as covariate. When adjusting 
for multiple comparisons using the Benjamini and Hochberg method all results remain 
significant with the exception of 20:0, 23:1, and 25:0 in the ACC and the 22:1 is no longer 
significant in the OCC when the analysis is adjusted for multiple comparisons (#). 
 
 
Figure 3: Quantitative real-time PCR analysis of ceramide synthase mRNA expression in 
control and PD brain samples. Control (n = 10) and PD (n = 9) tissues were collected from 
(A) the anterior cingulate cortex (“ACC”) and (B) the occipital cortex (“OCC”) and the levels 
of CerS gene expression analysed using qPCR. CerS mRNA levels were calculated relative to 
housekeeper cyclophylin A mRNA levels. Data for the expression each CerS gene in the PD 
samples is expressed relative to the control values (assigned a value of 1.0). Control samples 
are indicated by the grey bars and PD samples are indicated by the black bars. Differences 
between groups PD and Con were analysed using a linear mixed model to control for 
covariates and further adjustment for multiple comparisons was conducted using the 
Benjamini and Hochberg method (in this case the CerS4 is no longer significant in the ACC 
region (P=0.160) when the analysis is adjusted for multiple comparisons (#). Values are mean 
± SE. * P < 0.05. 
 
 
 
 
 
 
Table 1. Demographic details for control (Con) and Parkinson’s disease (PD) cohorts.  
Case # 
Gender 
(M/F) 
Post-mortem 
interval (h) 
Age at 
death (y) 
PD duration 
(y) 
Braak PD 
stage (0 – VI) 
Con 1 F 40.5 78 - 0 
Con 2 F 7.5 82 - 0 
Con 3 M 6.5 78 - 0 
Con 4 M 25 60 - 0 
Con 5 M 13.5 69 - 0 
Con 6 M 48 73 - 0 
Con 7 F 25 72 - 0 
Con 8 M 9 88 - 0 
Con 9 F 10 85 - 0 
Con 10 F 35 62 - 0 
PD 1 M 24# 75 n.a. IV 
PD 2 M 24# 71 n.a. IV 
PD 3 M 23 80 n.a. IV 
PD 4 F 6 75 10 IV 
PD 5 M 24# 74 n.a. IV 
PD 6 F 14 74 17 VI 
PD 7 M 24# 78 36 V 
PD 8 M 24# 85 8 IV 
PD 9 M 3 88 20 IV 
 
# Estimated PMI based on date of death and date of brain collection. 
n.a. Data not available. 
 
 
Table 2. Ceramide concentrations (nmol/g tissue wet weight) in anterior cingulate cortex (ACC) 
and occipital cortex (OCC) derived from control (n= 10) and Parkinson’s disease (PD) cases 
(n=9). 
 
ACC 
(Grey matter) 
 OCC 
(Grey matter) 
 Cer(d18:1)  
acyl chain 
structure Control PD p Control PD p 
16:0 12.5 ± 0.9 11.9 ± 1.3 0.833 14.6 ± 1.5 14.0 ± 2.1 0.857 
18:0 445.9 ± 29.5 271.2 ± 43.3 0.018 387.0 ± 40.9 326.2 ± 48.0 0.747 
18:1 11.9 ± 1.1 8.1 ± 1.2 0.007 10.8 ± 1.4 12.0 ± 2.4 0.413 
20:0 33.9 ± 0.8 20.3 ± 2.3* <0.001 27.3 ± 2.2 22.5 ± 2.5 0.193 
22:0 54.6 ± 4.4 21.6 ± 4.1* <0.001 29.6 ± 6.6 19.0 ± 3.6 0.276 
22:1 27.5 ± 1.5 14.0 ± 2.3* <0.001 18.0 ± 2.3 15.9 ± 2.1 0.593 
23:0 70.1 ± 5.8 26.5 ± 5.7* <0.001 32.0 ± 8.5 20.6 ± 5.2 0.395 
23:1 50.0 ± 2.7 27.9 ± 4.1* <0.001 30.1 ± 2.5 28.5 ± 3.5 0.765 
24:0 67.2 ± 7.2 28.5 ± 5.4* 0.001 32.2 ± 8.3 17.8 ± 3.5 0.216 
24:1 902.8 ± 61.8 356.3 ± 76.7* <0.001 487.8 ± 108.1 307.5 ± 65.9 0.261 
25:0 64.5 ± 3.0 35.0 ± 6.0* <0.001 45.1 ± 4.8 37.5 ± 4.4 0.310 
25:1 126.6 ± 9.0 58.2 ± 10.9* <0.001 67.9 ± 11.2 51.5 ± 7.9 0.342 
26:1 60.4 ± 4.9 26.1 ± 5.0* <0.001 1.5 ± 5.3 21.8 ± 3.0 0.192 
Total Ceramide 1927.9 ± 105.4 905.6 ± 162.0* <0.001 1214.0 ± 192.2 894.8 ± 143.6 0.281 
 
Values expressed as mean ± SE. P values represent the effect of group from multivariate 
analysis of covariance with region as the within subject factor and age and time since death as 
covariates. * indicates p value is still significant at the 0.05 level when further post hoc 
adjustment is done for the 26 individual comparisons using the Benjamini and Hochberg 
approach. 
 
Supplementary Table 1. Grey matter sphingomyelin concentrations (nmol/g tissue wet weight) in anterior 
cingulate cortex (ACC) and occipital cortex (OCC) derived from control and Parkinson’s disease (PD) cases. 
 
ACC 
(Grey matter) 
 OCC 
(Grey matter) 
 
SM(d18:1)  
acyl chain 
structure 
Control 
Mean         SE 
PD 
Mean         SE 
 
p 
Control 
Mean         SE 
PD 
Mean         SE 
 
p 
14:0 18.2 1.2 8.5* 2.7 0.004 3.83 2.59 3.71 1.48 0.857 
16:0 429.1 31.3 246.3* 22.0 <0.001 263.95 50.22 152.80 11.74 0.100 
17:0 48.6 4.2 28.9* 3.4 0.002 33.39 5.46 22.25 1.95 0.111 
18:0 3285.5 210.3 2007.2* 165.0 <0.001 1934.97 263.91 1445.91 110.56 0.140 
18:1 293.6 19.4 249.9 16.2 0.060 181.33 23.12 168.75 25.45 0.889 
20:0 337.6 24.1 386.4* 20.7 0.120 300.87 22.67 384.39 56.87 0.245 
22:0 228.0 19.7 116.9* 13.4 <0.001 135.48 29.86 71.94 7.84 0.130 
22:1 108.4 7.0 56.4* 7.4 <0.001 62.06 13.39 35.25 4.53 0.098 
23:0 320.7 33.1 116.1* 19.7 <0.001 142.48 41.81 73.11 11.52 0.304 
23:1 161.5 10.4 85.3* 13.8 0.001 91.76 20.88 56.80 8.95 0.191 
24:0 450.6 67.7 186.8* 31.7 0.003 116.41 33.41 61.24 17.25 0.265 
24:1 4021.5 358.7 1845.4* 348.7 0.001 2361.02 556.06 1191.14 193.84 0.107 
25:0 129.3 25.1 65.0* 18.0 0.001 47.63 16.77 25.93 5.83 0.559 
25:1 735.8 55.7 395.4* 70.7 <0.001 420.16 83.11 268.54 41.83 0.143 
26:1 569.5 60.0 222.3* 40.7 0.001 307.32 64.12 178.25 21.94 0.140 
Total 
SM 
11628.2 877.2 6777.9* 1062.7 <0.001 6398.83 1165.82 4136.29 334.14 0.130 
 
Values expressed as mean ± SE. P values represent the effect of group from multivariate analysis of covariance 
with region as the within subject factor and age and postmortem interval as covariates. * Indicates p value is still 
significant at the 0.05 level when further post hoc adjustment is done for the 26 individual comparisons using the 
Benjamini and Hochberg approach. 
 
 
Supplementary Table 2. White matter ceramide concentrations (nmol/g tissue wet weight) in anterior 
cingulate cortex (ACC) and occipital cortex (OCC) derived from control and Parkinson’s disease (PD) 
cases. 
 
ACC 
(White matter) 
 OCC 
(White matter) 
 
Cer(d18:1)  
acyl chain 
structure Control 
Mean         SE 
PD 
Mean         SE 
 
p 
Control 
Mean         SE 
PD 
Mean         SE 
 
p 
16:0 14.8 3.4 20.4 2.1 0.425 29.9 5.7 56.8 16.5 0.207 
18:0 46.9 4.3 42.4 4.1 0.804 58.2 8.3 140.1 40.0 0.028 
18:1 615.7 73.6 736.5 108.9 0.312 886.3 76.6 626.3* 74.3 0.048 
20:0 45.1 5.2 45.8 5.8 0.560 56.2 6.1 48.1 4.2 0.230 
22:0 62.2 4.2 57.8 4.3 0.738 82.7 9.8 95.3 16.8 0.002 
22:1 91.2 8.2 92.5 11.2 0.346 101.9 5.7 66.1* 7.5 0.978 
23:0 113.9 9.6 106.4 7.9 0.824 143.5 19.4 110.9 16.5 0.031 
23:1 114.7 11.4 120.6 17.8 0.366 116.1 6.4 81.9 12.2 0.141 
24:0 1593.7 162.9 1548.1 168.4 0.409 1798.0 96.8 1228.7* 213.1 0.004 
24:1 168.8 15.7 151.1 12.7 0.572 159.9 8.5 105.6 13.7 0.021 
25:0 258.8 26.8 261.0 24.6 0.917 277.8 20.9 225.7 38.4 0.031 
25:1 181.5 15.0 189.0 16.0 0.845 248.5 22.9 169.4 24.3 0.183 
26:1 131.6 16.2 124.8 11.5 0.672 141.1 7.8 91.8* 11.8 0.003 
Total 
Ceramide 
3438.7 334.1 3496.4 375.6 0.730 4100.2 248.3 3046.7* 402.1 0.032 
 
Values expressed as mean ± SE. P values represent the effect of group from multivariate analysis of covariance with 
region as the within subject factor and age and postmortem interval as covariates. * Indicates p value is still significant 
at the 0.05 level when further post hoc adjustment is done for the 26 individual comparisons using the Benjamini and 
Hochberg approach. 
 
Supplementary Table 3. White matter sphingomyelin concentrations (nmol/g tissue wet weight) in anterior cingulate 
cortex (ACC) and occipital cortex (OCC) derived from control and Parkinson’s disease (PD) cases. 
 
ACC 
(White matter) 
 OCC 
(White matter) 
 
SM(d18:1)  
acyl chain 
structure 
Control 
Mean         SE 
PD 
Mean         SE 
 
p 
Control 
Mean         SE 
PD 
Mean         SE 
 
p 
14:0 12.3 3.2 18.7 2.7 0.554 24.0 4.5 6.6 3.4 0.015 
16:0 543.3 17.3 553.6 26.2 0.968 791.2 55.4 505.7* 36.9 0.001 
17:0 68.9 3.1 73.6 6.6 0.675 95.3 9.2 59.9 11.2 0.014 
18:0 4090.4 170.4 4133.0 252.8 0.636 4939.7 237.8 3600.6* 209.0 0.001 
18:1 315.3 13.2 339.5 23.0 0.642 342.7 22.4 305.5 14.6 0.139 
20:0 350.5 20.2 321.5 14.0 0.308 283.7 19.2 376.6 26.1 0.017 
22:0 348.8 26.5 327.4 20.7 0.445 333.6 25.4 251.5* 20.2 0.004 
22:1 157.2 7.9 147.4 9.5 0.459 160.1 16.3 120.9 11.1 0.046 
23:0 491.1 35.8 414.9 28.6 0.110 368.8 18.0 337.0 28.5 0.289 
23:1 256.4 6.3 252.6 17.3 0.761 262.2 30.7 212.9 18.9 0.126 
24:0 741.5 96.5 519.8 66.0 0.112 500.3 58.6 313.3 26.9 0.017 
24:1 6356.5 277.6 5987.6 434.1 0.341 6398.8 546.1 4625.1 510.5 0.015 
25:0 279.8 36.8 229.7 33.9 0.155 210.7 22.1 114.3 18.8 0.010 
25:1 1168.6 53.4 1089.3 75.6 0.421 999.5 95.2 936.4 107.5 0.483 
26:1 888.8 68.3 758.6 47.1 0.207 706.7 51.3 554.0 45.1 0.018 
Total 
SM 
16057.0 683.9 15123.1 760.6 0.249 16393.2 1009.5 12313.6* 949.4 0.005 
 
Values expressed as mean ± SE. P values represent the effect of group from multivariate analysis of covariance with 
region as the within subject factor and age and postmortem interval as covariates. * Indicates p value is still significant 
at the 0.05 level when further post hoc adjustment is done for the 26 individual comparisons using the Benjamini and 
Hochberg approach. 
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